Amendment in Export Policy of Amphotericin B injections

## Report on Amendment to Export Policy of Amphotericin B Injections **1. Executive Summary:** This report analyzes an amendment to the export policy regarding Amphotericin B injections, as outlined in a notification issued by the Directorate General of Foreign Trade (DGFT) on June 1, 2021. This amendment, enacted under the Foreign Trade Development and Regulation Act of 1992, restricts the export of Amphotericin B injections, changing the previous policy from "Free" to "Restricted". This report details the specific changes, their potential impact, and relevant implementation aspects based solely on the provided policy text. The primary purpose of the amendment appears to be to control the availability of Amphotericin B injections, likely due to domestic needs. **2. Introduction:** This report provides an informative overview and analysis of the amendment to the export policy concerning Amphotericin B injections. The analysis is based exclusively on the provided notification issued by the Directorate General of Foreign Trade (DGFT) on June 1, 2021. The purpose of this report is to inform affected parties about the changes and their implications. **3. Policy Overview:** * **Original Policy:** The notification amends Schedule 2 of the ITC (HS) Export Policy, 2018, thereby impacting existing export regulations. * **Core Objective(s):** Based on the text, the core objective of this amendment is to restrict the export of Amphotericin B injections. This suggests a desire to control the supply of these injections. **4. Background and Rationale:** This is an amendment to an existing policy. The rationale for this specific amendment, inferring from the text, is likely to address a need to limit the export of Amphotericin B injections. The change from a "Free" to "Restricted" export policy suggests a potential shortage or increased domestic demand for this medication, prompting the government to prioritize domestic availability. The exact reasons (e.g., disease outbreak, manufacturing issues) are not provided in the text, but the restrictive action strongly implies supply concerns. **5. Key Provisions / Changes:** This section focuses specifically on the changes introduced by the provided amendment text: * **Specific Part of Original Policy Changed:** Schedule 2 of the ITC (HS) Export Policy, 2018, specifically entries related to Amphotericin B injections. * **New Rule/Provision:** The export policy for Amphotericin B injections, classified under ITC HS Codes Ex 30049029 and Ex 30049099, is changed from "Free" to "Restricted." * **Difference/Effect of Change:** The effect of this change is that exporting Amphotericin B injections is no longer permitted without specific authorization or under specific conditions that are not outlined in this document. Previously, such exports were unrestricted. This will likely require exporters to obtain licenses or permissions to export these injections, and the government can now control the volume of exports. **6. Target Audience and Stakeholders:** Based on the provided text, the primary target audience and stakeholders are: * Manufacturers and exporters of Amphotericin B injections. * Entities involved in the trade and distribution of these injections. * Customs authorities responsible for enforcing export regulations. **7. Implementation Aspects (Inferred):** * **Responsible Agency/Bodies:** The Directorate General of Foreign Trade (DGFT) is the responsible agency for issuing and implementing this amendment. Customs authorities would be involved in enforcing the restriction. * **Timelines/Procedures:** The amendment is effective immediately from June 1, 2021. The specific procedures for obtaining permission to export (if any are granted) are not detailed in this notification and would likely be outlined in separate guidelines or notifications. **8. Expected Outcomes / Impact of Changes:** The likely intended outcome of this amendment is to: * Prioritize domestic availability of Amphotericin B injections. * Potentially stabilize or reduce the domestic price of the injections by limiting export demand. * Ensure sufficient supply for domestic patients in need. * Negatively impact export revenues for manufacturers unless they can obtain necessary export permissions. * Increase the administrative burden for exporters who previously did not need to obtain export licenses. **9. Conclusion:** The amendment to the export policy of Amphotericin B injections represents a significant shift from a free export regime to a restricted one. This change, implemented by the DGFT, is likely driven by a need to ensure adequate domestic supply of this critical medication. Exporters need to be aware of these changes and comply with the new regulations, which took effect immediately on June 1, 2021. The significance of this amendment lies in its potential to directly impact the availability and pricing of Amphotericin B injections within the domestic market.

Key Entities Referenced